Journal of Biomaterials Science Polymer Edition · 2015 · 15 citations · 39 references
MedicineBioengineeringBiomedical EngineeringBone MetabolismDrug DeliveryNanoparticle Drug DeliveryBone Tissue EngineeringNanostructured BiomaterialsOsteoblast BiologyOsteoclast BiologyOsteogenesisSynthetic Bone SubstitutesBioactive Scaffold MaterialsBone Regeneration MaterialsHyaluronan InteractionsNanomaterials For Bone RegenerationNanostructured Bone SubstitutesOsteoblast Gene ExpressionOsteoinductivityPolysaccharide Natural Products
To treat the osteoporosis and regulate the biological behaviors of both osteoblasts and osteoclasts, we prepared a natural polysaccharide-derived nanocomposite, containing alendronate-grafted hyaluronate (HA-Aln) and bone morphogenetic protein 2 (BMP-2) and investigated its synergistic regulation on the behaviors of osteoblasts and osteoclasts in vitro. The HA-Aln/BMP-2 nanocomposite was fabricated through the electrostatic interactions between the HA-Aln molecule and BMP-2 molecule. Here, BMP-2 was used to improve the osteoblast-mediated bone formation. Alendronate (Aln), a targeting ligand to bone matrix, was used to inhibit the osteoclast-mediated bone resorption. In vitro results showed that HA-Aln/BMP-2 nanocomposite could effectively maintain the bioactivity of loaded drugs. The osteoblasts that treated with the HA-Aln/BMP-2 nanocomposite presented a higher level of cell motility, alkaline phosphatase (ALP) activity, mineralization capacity, and osteoblast-related gene expressions (runt-related transcription factor 2, osterix, ALP, collagen type I, osteocalcin, and osteopontin), as compared to that of control group. Besides, the RAW264.7 cells that were treated with HA-Aln/BMP-2 nanocomposite showed a lower level of osteoclastic differentiation. Overall, the HA-Aln/BMP-2 nanocomposite exhibits promising potential as an efficient carrier for co-delivery of anti-osteoporotic drug and growth factors to promote osteoblastic differentiation and bone formation while suppressing osteoclastic activity.
39
Effects of Continuing or Stopping Alendronate After 5 Years of Treatment
Dennis M. Black, Ann V. Schwartz, Kristine E. Ensrud et al. · JAMA · 2006 · 1.4K citations